Innate Pharma (IPHA) shares fell 4.9% in recent Thursday trading after downgrades by Leerink and HC Wainwright.
Leerink downgraded the stock to market perform from outperform and adjusted its price target to $2 from $10. HC Wainwright lowered its rating to neutral from buy.
Innate Pharma's intraday volume topped 12,300 shares, versus the daily average of 11,987.
Price: 1.95, Change: -0.10, Percent Change: -4.88